High performance liquid chromatography (HPLC) is routinely used for de
termination of both assay and impurities in both bulk active and formu
lated drug products. Impurity profile analyses are required to demonst
rate the ability to detect a wide range of impurities which may occur
in pharmaceuticals. However, most impurity profile methods do not addr
ess the potential of co-elution of impurities with product peaks. UV p
hotodiode array detection (PDA) evaluates the UV and/or the UV/VIS spe
ctrum of an eluting species to determine spectral homogeneity. If vari
ations in tile spectrum are observed, the possibility of a co-eluting
impurity must be addressed. By establishing consistent evaluations HPL
C-PDA can be used to more accurately assess impurity levels and provid
e analyses with much higher informational content.